Low-quality drugs in India raise concerns | Chemical & Engineering News
Volume 94 Issue 9 | p. 19 | Concentrates
Issue Date: February 29, 2016

Low-quality drugs in India raise concerns

By K. V. Venkatasubramanian, Special to C&EN
Department: Government & Policy
Keywords: pharmaceuticals, Asia, consumer safety, India, drug quality

Indian researchers have found that significant percentages of diclofenac sodium, a painkiller, and amoxicillin trihydrate, an antibiotic, sold in the country are of low quality. The published findings by a team led by Ahmed Nawaz Khan, assistant professor of pharmacy at Jaypee University of Information Technology, showed a higher percentage than the government’s national estimates for drugs that are substandard, meaning the products do not meet quality benchmarks (J. Appl. Pharm. Sci. 2015, DOI: 10.7324/japs.2015.501226; Int. J. Pharm. Pharm. Sci., 2016, 8,386). Khan told C&EN, “Out of 32 samples of diclofenac sodium products, we found 15.62% substandard, and out of 46 amoxicillin trihydrate products, we found 13.04% substandard, which indicate an alarming situation.” Khan says the samples don’t represent the nation’s overall drug supplies but raise questions about the quality of other drugs sold in India. Last December, surveys by the Central Drugs Standard Control Organization, India’s regulatory authority, had shown that only about 4.5% of the drugs in the Indian market are substandard.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment